Influence of a complex tratment on serum lipid profile and clinical course of ischemic heart disease in workers of mining industry.

V. I. Fesenko; V. A. Роtabashniy

doi:10.26641/2307-0404.2016.1.63472

Авторы

V. I. Fesenko
V. A. Роtabashniy

DOI:

https://doi.org/10.26641/2307-0404.2016.1.63472

Ключевые слова:

ischemic heart disease, silent ischemia, lipid metabolism, plasma hemostasis, miners

Аннотация

The aim of our study was to investigate the effectiveness of combined therapy with antiplatelet agent clopidogrel (Plagril^®, “Dr. Reddy’sLaboratories Limited”, India), and lipid-lowering agent atorvastatin (Atocor^®, “Dr. Reddy’s Laboratories Limited”, India) in the treatment of the miners with ischemic heart disease. A total of 30 miners have been under study. Complete physical examination, blood and urine tests, blood biochemistry, serum parameters of hemostasis, electrocardiogram, echocardiography, 24-hour ECG monitoring were performed. The treatment period was 3 months. It was established, that statin therapy with “Atocor” in combination with antiplatelet agent “Plagril” was well tolerated. The combination of medications significantly improves the clinical status of patients with coronary artery disease, along with effective correction of dyslipidemia without a negative impact on plasma hemostasis.

Биографии авторов

V. I. Fesenko

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Faculty of Postgraduate Education
Department therapy, cardiology and family medicine
Dzerzhinsky str., 9, Dnipropetrovsk, 49044, Ukraine

V. A. Роtabashniy

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Faculty of Postgraduate Education
Department therapy, cardiology and family medicine
Dzerzhinsky str., 9, Dnipropetrovsk, 49044, Ukraine

Библиографические ссылки

Bratus’ VV, Shumakov VA, Talayeva TV. [Athe-rosclerosis, ischemic heart disease, acute coronary syn-drome]. Kyiv: Chetverta Khvylya; 2004. Russian.

Bubnova MG. [Atorvastatin: lipid-lowering and pleiotropic properties and effectiveness in prophylaxis of atherosclerosis and coronary artery disease]. Cardiologia. 2004;49-57. Russian.

Vasylenko AM. [State of circulation and cardio-respiratory system in miners on the stage of stabilization of arterial hypertension]. Kyiv; 1994. Russian.

Volkov VI, Zaproval’naya OY. [Primary pre-vention and treatment of atherosclerosis]. Ukrayns’ky terapevtychny Juornal. 2002;4:6-15. Russian.

Kobets GP, Cherkesov VV, Kopytyna RA. [Ischemic heart disease at miners]. Kyiv: Zdorovya; 1995. Russian.

Kovalenko VM. [Atherosclerosis and associated organ diseases: common strategy of prophylaxis stages of specialized treatment]. Ukrayns’ky cardiologychny Juor¬nal. 2007;5:8-11. Ukrainian.

Lutay MI, Lysenko AF. [Dyslipidemias: clinical sig¬nificance]. Mystetstvo likuvannya. 2003;1:12-16. Ukrainian.

Kovalenko VM. [Health Condition of Ukrainian Nation in connection with cardiovascular diseases and possible improvement strategies]. Kyiv; 2004. Ukrainian.

Kovalenko VM, Kornatsky VM. [Cardiovascular diseases as medical, social and political problem]. Kyiv; 2014. Ukrainian.

Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC,Williams SV. (2002) ACC/ AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology /American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina).

Michelson AD, Cattaneo M, Eikelboom JW et al. As¬pirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3:1309-11.

Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 ran-domised trials of statins. Lancet 2005;366:1267-78.

Patrono C, Bachmann F, Baigent C et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J. 2004;25:166-81.

Lim MJ, Cpencer FA, Gore JM et al. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment ele¬vation acute coronary syndromes: perspectives from a lar¬ge multinational registry/ Eur. Heart J. 2005;26:1063-69.

Patrono C, Coller В, Fitzgerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Confe-rence on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3):234S-264S. 16. Fox K, Angeles M, Garcia A, Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 2006;27(11):1341-81.